Patents by Inventor Audris Huang

Audris Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IDO INHIBITORS
    Publication number: 20160200674
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention.
    Type: Application
    Filed: August 26, 2014
    Publication date: July 14, 2016
    Applicant: Bristol-Myers Squibb Company
    Inventors: Jay A. Markwalder, Steven P. Seitz, James Aaron Balog, Audris Huang, Sunil Kumar Mandal, Shefali Srivastava, David K. Williams, Libing Chen
  • IDO INHIBITORS
    Publication number: 20160143870
    Abstract: There are disclosed compounds of Formula (I) that modulate or inhibit the enzymatic activity of indoleamine 2,3-di-oxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention.
    Type: Application
    Filed: July 10, 2014
    Publication date: May 26, 2016
    Inventors: Jay A Markwalder, James Aaron Balog, Audris Huang, Steven P Seitz
  • IMMUNOREGULATORY AGENTS
    Publication number: 20160137653
    Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.
    Type: Application
    Filed: November 5, 2015
    Publication date: May 19, 2016
    Inventors: Hilary Plake Beck, Juan Carlos Jaen, Maksim Osipov, Jay Patrick Powers, Maureen Kay Reilly, Hunter Paul Shunatona, James Ross Walker, Mikhail Zibinsky, James Aaron Balog, David K. Williams, Jay A. Markwalder, Steven P. Seitz, Emily Charlotte Cherney, Liping Zhang, Weifang Shan, Weiwei Guo, Audris Huang
  • IDO INHIBITORS
    Publication number: 20160137595
    Abstract: There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine 2,3-di-oxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Application
    Filed: July 1, 2014
    Publication date: May 19, 2016
    Inventors: Jay A. Markwalder, Steven P. Seitz, James Aaron Balog, Audris Huang, Sunil Kumar Mandal, David K. William, Amy C. Hart, Jennifer Inghrim
  • IMMUNOREGULATORY AGENTS
    Publication number: 20160137652
    Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.
    Type: Application
    Filed: November 5, 2015
    Publication date: May 19, 2016
    Inventors: Hilary Plake Beck, Juan Carlos Jaen, Maksim Osipov, Jay Patrick Powers, Maureen Kay Reilly, Hunter Paul Shunatona, James Ross Walker, Mikhail Zibinsky, James Aaron Balog, David K. Williams, Jay A. Markwalder, Emily Charlotte Cherney, Weifang Shan, Audris Huang
  • SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS
    Publication number: 20160096847
    Abstract: Disclosed are azaindazole compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: X is O and Y is N; or X is S and Y is CH; Z is CR2 or N; Q is a heteroaryl; and R1 is defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP 17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: December 14, 2015
    Publication date: April 7, 2016
    Inventors: James Aaron Balog, Audris Huang
  • IDO INHIBITORS
    Publication number: 20160060237
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention. Formula (I).
    Type: Application
    Filed: March 12, 2014
    Publication date: March 3, 2016
    Inventors: James Aaron Balog, Audris Huang, Bin Chen, Libing Chen, Weifang Shan
  • INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO)
    Publication number: 20160022619
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Application
    Filed: March 12, 2014
    Publication date: January 28, 2016
    Inventors: James Aaron Balog, Audris Huang, Bin Chen, Libing Chen, Steven P. Seitz, Amy C. Hart, Jay A. Markwalder
  • Substituted benzimidazole and imidazopyridine compounds useful as CYP17 modulators
    Patent number: 9133160
    Abstract: Disclosed are heteroaryl compounds of Formula (I), (I), or pharmaceutically acceptable salts thereof, wherein Z is CH or N; W is CR3 or N; and R1, R2, and R3 are defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: September 15, 2015
    Assignee: Bristol-Meyers Squibb Company
    Inventor: Audris Huang
  • Substituted bicyclic heteroaryl compounds
    Patent number: 8969586
    Abstract: Disclosed are azaindazole compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: X is O and Y is N; or X is S and Y is CH; Z is CR2 or N; Q is a heteroaryl; and R1 is defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: March 3, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: James Aaron Balog, Audris Huang
  • Sulfonamide compounds useful as CYP17 inhibitors
    Patent number: 8916553
    Abstract: Disclosed are sulfonamide compounds of Formula (I): or stereoisomers, N-oxides, prodrugs, or pharmaceutically acceptable salts thereof, wherein ring A, R1, R2, R3, R4 and R5 are defined herein. Also disclosed are methods of using such compounds in the treatment of conditions related to CYP17 enzyme, such as cancer, and pharmaceutical compositions comprising such compounds.
    Type: Grant
    Filed: July 25, 2011
    Date of Patent: December 23, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Joel Francis Austin, Lisa S. Sharma, James Aaron Balog, Audris Huang, Upender Velaparthi, Chetan Padmakar Darne, Mark George Saulnier
  • SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS
    Publication number: 20140235647
    Abstract: Disclosed are azaindazole compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: X is O and Y is N; or X is S and Y is CH; Z is CR2 or N; Q is a heteroaryl; and R1 is defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: September 27, 2012
    Publication date: August 21, 2014
    Inventors: James Aaron Balog, Audris Huang, Upender Velaparthi, Peiying Liu
  • SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS
    Publication number: 20140148453
    Abstract: Disclosed are sulfonamide compounds of Formula (I): or stereoisomers, N-oxides, prodrugs, or pharmaceutically acceptable salts thereof, wherein ring A, R1, R2, R3, R4 and R5 are defined herein. Also disclosed are methods of using such compounds in the treatment of conditions related to CYP17 enzyme, such as cancer, and pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: July 25, 2011
    Publication date: May 29, 2014
    Inventors: Joel Francis Austin, Lisa S. Sharma, James Aaron Balog, Audris Huang, Upender Velaparthi, Chetan Padmakar Darne, Mark George Saulnier
  • Azaindazole compounds
    Patent number: 8673922
    Abstract: Disclosed are azaindazole compounds of Formula (I), or pharmaceutically acceptable salts thereof, wherein W is CR4 or N; and R1, R2, R3, and R4 are defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.
    Type: Grant
    Filed: July 14, 2011
    Date of Patent: March 18, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Upender Velaparthi, David B. Frennesson, Mark G. Saulnier, Joel F. Austin, Audris Huang, James Aaron Balog, Dolatrai M. Vyas
  • SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE COMPOUNDS USEFUL AS CYP17 MODULATORS
    Publication number: 20130310393
    Abstract: Disclosed are heteroaryl compounds of Formula (I), (I), or pharmaceutically acceptable salts thereof, wherein Z is CH or N; W is CR3 or N; and R1, R2, and R3 are defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: September 23, 2011
    Publication date: November 21, 2013
    Applicant: Bristol-Myers Squibb Company
    Inventor: Audris Huang
  • AZAINDAZOLE COMPOUNDS
    Publication number: 20130184254
    Abstract: Disclosed are azaindazole compounds of Formula (I), or pharmaceutically acceptable salts thereof, wherein W is CR4 or N; and R1, R2, R3, and R4 are defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: July 14, 2011
    Publication date: July 18, 2013
    Inventors: Upender Velaparthi, David B. Frennesson, Mark G. Saulnier, Joel F. Austin, Audris Huang, James Aaron Balog, Dolatrai M. Vyas
  • Substituted quinolinecarboxamides as antiviral agents
    Patent number: 6727248
    Abstract: The present invention discloses disubstiuted 4-oxo-1,4-dihydro-3-quinolinecarboxamide derivatives. The compounds are useful as antiviral agents, in particular, as agents against viruses of the herpes family.
    Type: Grant
    Filed: January 23, 2003
    Date of Patent: April 27, 2004
    Assignee: Pharmacia & Upjohn Company
    Inventors: Valerie A. Vaillancourt, Audris Huang
  • Pyrroloquinolones as antiviral agents
    Patent number: 6683181
    Abstract: The present invention provides a compound of formula I which is useful as antiviral agents, in particular, as agents against viruses of the herpes family.
    Type: Grant
    Filed: November 5, 2002
    Date of Patent: January 27, 2004
    Assignee: Pharmacia and Upjohn Comapny
    Inventors: Valerie A. Vaillancourt, Sandra Staley, Audris Huang, Richard Allen Nugent, Ke Chen, Sajiv K. Nair, James A. Nieman, Joseph Walter Strohbach
  • Pyrroloquinolones as antiviral agents
    Publication number: 20030153561
    Abstract: The present invention provides a compound of formula I 1
    Type: Application
    Filed: November 5, 2002
    Publication date: August 14, 2003
    Inventors: Valerie A. Vaillancourt, Sandra Staley, Audris Huang, Richard Allen Nugent, Ke Chen, Sajiv K. Nair, James A. Nieman, Joseph Walter Strohbach
  • Substituted quinolinecarboxamides as antiviral agents
    Publication number: 20030149035
    Abstract: The present invention discloses disubstiuted 4-oxo-1,4-dihydro-3-quinolinecarboxamide derivatives. The compounds are useful as antiviral agents, in particular, as agents against viruses of the herpes family.
    Type: Application
    Filed: January 23, 2003
    Publication date: August 7, 2003
    Inventors: Valerie A. Vaillancourt, Audris Huang